• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Regeneron, Bayer report positive Phase III results for DME treatment


Regeneron Pharmaceuticals and Bayer HealthCare have announced that in the Phase III trials of Eylea (aflibercept) injection for treating DME, Eylea 2 mg achieved significantly greater improvement in BCVA from baseline compared with laser photocoagulation at 52 weeks.


Tarrytown, NY-Regeneron Pharmaceuticals Inc. and Bayer HealthCare have announced that in the Phase III VIVID-DME and VISTA-DME trials of Eylea (aflibercept) injection for treating diabetic macular edema (DME), Eylea 2 mg dosed monthly and Eylea 2 mg dosed every 2 months (after 5 initial monthly injections) achieved the primary endpoint of a significantly greater improvement in best-corrected visual acuity (BCVA) from baseline compared with laser photocoagulation at 52 weeks.

Based on discussions with the FDA, Regeneron expects to submit an application for U.S. marketing approval for Eylea in 2013, approximately 1 year earlier than previously planned. Bayer Healthcare plans to submit an application this year for marketing approval for the treatment of DME in Europe.

In the VIVID-DME and VISTA-DME trials, Eylea was generally well tolerated with a similar overall incidence of adverse events (AEs), ocular serious AEs, and non-ocular serious AEs across the treatment groups and a laser control group. Arterial thromboembolic events also occurred at similar rates across the treatment groups and the laser control group.

The most frequent ocular treatment emergent AEs (TEAEs) observed in the VIVID-DME and VISTA-DME trials included conjunctival hemorrhage, eye pain, and vitreous floaters. The most frequent non-ocular TEAEs included hypertension and nasopharyngitis, which occurred with similar frequency in the treatment groups and the laser control group. 

Related Videos
Andy Morgenstern, OD, FAAO, FNAP chats with Optometry Times
R Tracy Williams, OD, FAAO with Optometry Times
Shan Lin, MD, speaks on Glaucoma 360 presentation in an interview with Ophthalmology Times
Cecelia Koetting, OD, FAAO, DIPABO, left, speaks with Optometry Times about the 2024 EnVision Summit
Bonnie An Henderson, MD, highlights key takeaways of the 2024 EnVision Summit, including diversity and family inclusion
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Robert Weiss, former CEO and President of The Cooper Companies, Inc. (left) and Optometry Times' Assistant Managing Editor Emily Kaiser Maharjan Image Credit ©Optometry Times
© 2024 MJH Life Sciences

All rights reserved.